Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital, reporting preliminary PET imaging data that show encouraging signals in acute MS lesions. The study evaluates a novel imaging technique designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, offering a potentially more precise method to measure myelin loss and repair.
The significance of this development lies in its direct relevance to Lucid-MS, the company's investigational compound aimed at inhibiting demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool combined with a drug candidate designed to address the underlying cause of MS presents a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions, according to a recent article.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company has also invented unbuzzd, a product designed to address alcohol misuse, and spun out its OTC version to Unbuzzd Wellness Inc. (UWI). Quantum BioPharma retains ownership of 19.84% of UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
Investors can stay updated on the latest news and developments regarding QNTM through the company's newsroom at https://nnw.fm/QNTM. For more information about Quantum BioPharma, visit the company's website or review the full article at https://nnw.fm/fsDHa.
